FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to otorhinolaryngology, and may be used for diagnosing a vasomotor phenotype of chronic rhinosinusitis without nasal polyps. A rhinocytogram is performed, and cytokine concentrations are examined: interleukin 6 – IL-6, interleukin 10 – IL-10, interferon alpha – INFa, in nasopharyngeal wash, taking into account patient's sex. Diagnosis is carried out in patients with clinical manifestations of chronic rhinosinusitis. A diagnostic criterion Y is calculated by formula: Y = (EXP (Z) / (1 + EXP (Z))) × 100%, where Z = (1.33 - (X1 × 0.17) - (X2 × 0.29) - (X3 × 1.17) + (X4 × 0.39)+ (X5 × 0.68) + (X6 × 0.09) + (X7 × 0.001) - (X8 × 0.02) + (X9 × 0.04) + (X10 × 0.07), where: Y is the diagnostic significance of the formation of a vasomotor phenotype of chronic rhinosinusitis without nasal polyps, %; X1 is the severity of exudative reactions according to the rhinocytogram: 0 – absence of exudative reactions, 1 – insignificant exudative reactions – 1/3 of field of vision in mucus, 2 – moderate exudative reactions – 1/2 of field of vision in mucus, 3 – pronounced exudative reactions – entire field of vision in mucus; X2 is patient's sex: 1 – women, 2 – men; X3 is presence of coccal microflora in rhinocytogram: 0 – absence of coccal microflora, 1 – presence of coccal microflora; X4 is the specific weight of lymphocytes in the leukocyte formula of rhinocytogram, %; X5 is the intensity of coccal microflora in the rhinocytogram: 0 – absence of coccal microflora, 1 – insignificant presence – 1-10 bacterial cells in field of vision, 2 – moderate presence – 11-20 bacterial cells in field of vision, 3 – pronounced presence – more than 21 bacterial cells in field of vision; X6 is expression of pavement non-functional epithelium by rhinocytogram: 0 – absence of pavement non-functional epithelium, 1 – insignificant presence of pavement epithelium – 1-10 epithelial cells in field of vision, 2 – moderate presence of pavement epithelium – 11-20 epithelial cells in field of vision, 3 – pronounced presence of pavement epithelium – more than 21 epithelial cells in field of vision; X7 is the concentration of IL-6 in the nasopharyngeal wash, pg/ml; X8 is concentration of INFa in nasopharyngeal wash, pg/ml; X9 is the severity of leukocyte reactions according to the rhinocytogram: 0 – absence of leukocyte reactions, 1 – insignificant leukocyte reactions – 1-10 leukocytes in field of vision, 2 – moderate leukocyte reaction – 11-20 leukocytes in field of vision, 3 – pronounced leukocyte reactions – more than 21 leukocytes in field of vision; X10 is concentration of IL-10 in nasopharyngeal wash, pg/ml; 1.33 is the absolute term of the logistic model. If Y is 68 % or more, a vasomotor phenotype of chronic rhinosinusitis with no nasal polyps is diagnosed.
EFFECT: method enables to diagnose the vasomotor phenotype of chronic rhinosinusitis without nasal polyps by determining dominant predictors and protectors associated with the vasomotor phenotype of chronic rhinosinusitis without nasal polyps, detected by logistic regression from the analysis of rhinocytogram values and cytokine concentrations: IL-6, IL-10 and INFa, nasopharyngeal washing taking into account patient's sex.
1 cl, 4 dwg, 1 tbl, 1 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR ASSESSING COMPOSITION OF BIOPSY MATERIAL OF NASAL MUCOSA | 2022 |
|
RU2819990C1 |
METHOD FOR DIFFERENTIAL DIAGNOSIS OF CHRONIC RHINOSINUSITIS IN CHILDREN | 2023 |
|
RU2816051C1 |
METHOD FOR PHENOTYPE DETERMINATION OF CHRONIC INFLAMMATORY DISEASES OF NOSE AND PARANASAL SINUSES IN CASE OF INDICATIONS FOR TARGETED THERAPY | 2023 |
|
RU2826780C1 |
METHOD FOR SELECTING TARGETED THERAPY IN CHRONIC T2-INFLAMMATORY DISEASES OF NASAL CAVITY AND PARANASAL SINUSES | 2023 |
|
RU2824263C1 |
METHOD FOR PREDICTION OF EFFICIENCY OF SURGICAL TREATMENT OF CHILDREN WITH CHRONIC RHINOSINUSITIS | 2023 |
|
RU2817091C1 |
METHOD FOR EVALUATING EFFICIENCY IN TREATMENT OF RHINOSINUSITES | 2001 |
|
RU2200319C1 |
METHOD OF TREATING CHRONIC RECURRING INFLAMMATORY DISEASES OF NASAL CAVITY AND PARANASAL SINISES BY METHOD OF ENDONASAL AUTOLYMPHOCYTO THERAPY | 2009 |
|
RU2403071C1 |
METHOD OF TREATING CHRONIC RHINOSINUSITIS | 2011 |
|
RU2469737C1 |
METHOD OF PREDICTING THE RISK OF DEVELOPING RESPIRATORY DISEASES IN WORKERS INVOLVED IN THE PRODUCTION OF SYNTHETIC DETERGENTS | 2022 |
|
RU2802198C1 |
METHOD TREATMENT OF VASOMOTOR RHINITIS | 1996 |
|
RU2136334C1 |
Authors
Dates
2025-05-23—Published
2024-07-23—Filed